Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 5/20 | 0.49 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.41 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.41 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 5/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 3/20 | 0.36 |
| ▸ | PARP2 | Q9UGN5 | 3/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL17965628 | 0.81 | PNMT (0.71) | PNMTTPSAB1TPSD1TPSG1ITGB3 | |
| Trifluoroacetic Acid SCHEMBL8457040 | 0.81 | PNMT (0.62) | PNMTTPSAB1TPSD1TPSG1ITGB3 | |
| SCHEMBL17965647 | 0.79 | PNMT (0.50) | PNMTTPSAB1TPSD1TPSG1ITGB3 | |
| SCHEMBL15903731 | 0.79 | POLB (0.60) | PNMTTPSAB1TPSD1TPSG1ITGB3 | |
| Trifluoroacetic Acid SCHEMBL31078582 | 0.78 | PNMT (0.81) | PNMTTPSAB1TPSD1TPSG1ITGB3 | |
| Hydrochloric Acid SCHEMBL7987429 | 0.77 | POLB (0.59) | PNMTTPSAB1TPSD1TPSG1ITGB3 | |
| Trifluoroacetic Acid SCHEMBL5648145 | 0.75 | PNMT (0.46) | PNMTTPSAB1TPSD1TPSG1ITGB3 | |
| Trifluoroacetic Acid SCHEMBL5648133 | 0.75 | PNMT (0.46) | PNMTTPSAB1TPSD1TPSG1ITGB3 | |
| Trifluoroacetic Acid SCHEMBL29721315 | 0.75 | PNMT (0.55) | PNMTTPSAB1TPSD1TPSG1ITGB3 | |
| SCHEMBL23474357 | 0.71 | PNMT (0.56) | PNMTTPSAB1TPSD1TPSG1ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160237071-A1 | T-TYPE CALCIUM CHANNEL INHIBITOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-08-18 | — | — | US | disclosed |
| EP-3053917-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | Nissan Chemical Industries, Ltd. (JP) | 2016-08-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237071-A1 | T-TYPE CALCIUM CHANNEL INHIBITOR | CACNA1I, CACNA1G, CACNA1H | PNMT 4208/4885TPSAB1 1091/4885TPSD1 383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.